Cargando…

Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-β but Higher Levels of IL-1α and TGF-β

Purpose: SARS-CoV-2 infection induces in some patients a condition called long-COVID-19, herein post-COVID-19 (PC), which persists for longer than the negative oral-pharyngeal swab. One of the complications of PC is pulmonary fibrosis. The purpose of this study was to identify blood biomarkers to pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Colarusso, Chiara, Maglio, Angelantonio, Terlizzi, Michela, Vitale, Carolina, Molino, Antonio, Pinto, Aldo, Vatrella, Alessandro, Sorrentino, Rosalinda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698335/
https://www.ncbi.nlm.nih.gov/pubmed/34944747
http://dx.doi.org/10.3390/biomedicines9121931
_version_ 1784620252353527808
author Colarusso, Chiara
Maglio, Angelantonio
Terlizzi, Michela
Vitale, Carolina
Molino, Antonio
Pinto, Aldo
Vatrella, Alessandro
Sorrentino, Rosalinda
author_facet Colarusso, Chiara
Maglio, Angelantonio
Terlizzi, Michela
Vitale, Carolina
Molino, Antonio
Pinto, Aldo
Vatrella, Alessandro
Sorrentino, Rosalinda
author_sort Colarusso, Chiara
collection PubMed
description Purpose: SARS-CoV-2 infection induces in some patients a condition called long-COVID-19, herein post-COVID-19 (PC), which persists for longer than the negative oral-pharyngeal swab. One of the complications of PC is pulmonary fibrosis. The purpose of this study was to identify blood biomarkers to predict PC patients undergoing pulmonary fibrosis. Patients and Methods: We analyzed blood samples of healthy, anti-SARS-CoV-2 vaccinated (VAX) subjects and PC patients who were stratified according to the severity of the disease and chest computed tomography (CT) scan data. Results: The inflammatory C reactive protein (CRP), complement complex C5b-9, LDH, but not IL-6, were higher in PC patients, independent of the severity of the disease and lung fibrotic areas. Interestingly, PC patients with ground-glass opacities (as revealed by chest CT scan) were characterized by higher plasma levels of IL-1α, CXCL-10, TGF-β, but not of IFN-β, compared to healthy and VAX subjects. In particular, 19 out of 23 (82.6%) severe PC and 8 out of 29 (27.6%) moderate PC patients presented signs of lung fibrosis, associated to lower levels of IFN-β, but higher IL-1α and TGF-β. Conclusions: We found that higher IL-1α and TGF-β and lower plasma levels of IFN-β could predict an increased relative risk (RR = 2.8) of lung fibrosis-like changes in PC patients.
format Online
Article
Text
id pubmed-8698335
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86983352021-12-24 Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-β but Higher Levels of IL-1α and TGF-β Colarusso, Chiara Maglio, Angelantonio Terlizzi, Michela Vitale, Carolina Molino, Antonio Pinto, Aldo Vatrella, Alessandro Sorrentino, Rosalinda Biomedicines Article Purpose: SARS-CoV-2 infection induces in some patients a condition called long-COVID-19, herein post-COVID-19 (PC), which persists for longer than the negative oral-pharyngeal swab. One of the complications of PC is pulmonary fibrosis. The purpose of this study was to identify blood biomarkers to predict PC patients undergoing pulmonary fibrosis. Patients and Methods: We analyzed blood samples of healthy, anti-SARS-CoV-2 vaccinated (VAX) subjects and PC patients who were stratified according to the severity of the disease and chest computed tomography (CT) scan data. Results: The inflammatory C reactive protein (CRP), complement complex C5b-9, LDH, but not IL-6, were higher in PC patients, independent of the severity of the disease and lung fibrotic areas. Interestingly, PC patients with ground-glass opacities (as revealed by chest CT scan) were characterized by higher plasma levels of IL-1α, CXCL-10, TGF-β, but not of IFN-β, compared to healthy and VAX subjects. In particular, 19 out of 23 (82.6%) severe PC and 8 out of 29 (27.6%) moderate PC patients presented signs of lung fibrosis, associated to lower levels of IFN-β, but higher IL-1α and TGF-β. Conclusions: We found that higher IL-1α and TGF-β and lower plasma levels of IFN-β could predict an increased relative risk (RR = 2.8) of lung fibrosis-like changes in PC patients. MDPI 2021-12-17 /pmc/articles/PMC8698335/ /pubmed/34944747 http://dx.doi.org/10.3390/biomedicines9121931 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Colarusso, Chiara
Maglio, Angelantonio
Terlizzi, Michela
Vitale, Carolina
Molino, Antonio
Pinto, Aldo
Vatrella, Alessandro
Sorrentino, Rosalinda
Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-β but Higher Levels of IL-1α and TGF-β
title Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-β but Higher Levels of IL-1α and TGF-β
title_full Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-β but Higher Levels of IL-1α and TGF-β
title_fullStr Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-β but Higher Levels of IL-1α and TGF-β
title_full_unstemmed Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-β but Higher Levels of IL-1α and TGF-β
title_short Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-β but Higher Levels of IL-1α and TGF-β
title_sort post-covid-19 patients who develop lung fibrotic-like changes have lower circulating levels of ifn-β but higher levels of il-1α and tgf-β
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698335/
https://www.ncbi.nlm.nih.gov/pubmed/34944747
http://dx.doi.org/10.3390/biomedicines9121931
work_keys_str_mv AT colarussochiara postcovid19patientswhodeveloplungfibroticlikechangeshavelowercirculatinglevelsofifnbbuthigherlevelsofil1aandtgfb
AT maglioangelantonio postcovid19patientswhodeveloplungfibroticlikechangeshavelowercirculatinglevelsofifnbbuthigherlevelsofil1aandtgfb
AT terlizzimichela postcovid19patientswhodeveloplungfibroticlikechangeshavelowercirculatinglevelsofifnbbuthigherlevelsofil1aandtgfb
AT vitalecarolina postcovid19patientswhodeveloplungfibroticlikechangeshavelowercirculatinglevelsofifnbbuthigherlevelsofil1aandtgfb
AT molinoantonio postcovid19patientswhodeveloplungfibroticlikechangeshavelowercirculatinglevelsofifnbbuthigherlevelsofil1aandtgfb
AT pintoaldo postcovid19patientswhodeveloplungfibroticlikechangeshavelowercirculatinglevelsofifnbbuthigherlevelsofil1aandtgfb
AT vatrellaalessandro postcovid19patientswhodeveloplungfibroticlikechangeshavelowercirculatinglevelsofifnbbuthigherlevelsofil1aandtgfb
AT sorrentinorosalinda postcovid19patientswhodeveloplungfibroticlikechangeshavelowercirculatinglevelsofifnbbuthigherlevelsofil1aandtgfb